Category: HIV infection
PROVIDENCE, R.I. [Brown University] -- Contrary to conventional wisdom, scientific evidence proving that overlapping multiple sexual partners -- concurrency -- drives the HIV epidemic in sub-Saharan Africa is actually quite limited, Brown University researchers have concluded.
Arlington, Va. -- Medical providers on the front lines of HIV care applaud the U.S. Congress for extending the Ryan White HIV/AIDS Program, helping to ensure that more than half a million low-income, uninsured, or underinsured people living with HIV/AIDS have access to lifesaving care.
Yesterday saw the release of the paper published in the New England Journal of Medicine containing the hotly awaited data concerning the RV144 HIV vaccine trial that took place in Thailand. There was already some discussion of the initial results, which were reported in September and discussed by Colin and Martin. As has already been discussed, there is a very cautious consensus due to the statistical analysis of the trial only *just* falling on the side of significant. Click here to read this post in its native environment, on Blue-Genes.net.
PITTSBURGH, Oct. 13 -- While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.
The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.
HIV prevalence among African Americans is ten times greater than the prevalence among whites. This racial disparity in HIV prevalence has persisted in the face of both governmental and private actions, involving many billions of dollars, to combat HIV.
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S.
Scientists working to develop a vaccine for the human immunodeficiency virus (HIV) report they have created the first antigen that induces protective antibodies capable of blocking infection of human cells by genetically-diverse strains of HIV.
ATLANTA - A study of how HIV mutates in response to immune system pressure by Emory Vaccine Center researchers shows that the virus can take several escape routes, not one preferred route.
The results are online and scheduled for publication in the September issue of the journal Public Library of Science Pathogens.
By adapting a single protein on the surface of the bacterium Caulobacter crescentus, researchers at the University of British Columbia have turned it into a protein production factory, making useful proteins that can act as vaccines and drugs. Dr.
New research from UCSF examining HIV among men who have sex with men (MSM) in the township of Soweto in South Africa has found that a third of gay-identified men are infected with HIV.
Patients infected with a particular subtype of HIV, the virus that causes AIDS, are more likely to develop dementia than patients with other subtypes, a study led by Johns Hopkins researchers shows.
MADISON -- With the help of the human immunodeficiency virus (HIV) and molecular engineering, researchers have designed synthetic protein-like mimics convincing enough to interrupt unwanted biological conversations between cells.
Arlington, Va. -- With HIV patients living longer thanks to advances in treatment, the primary care needs of those living with HIV have never been more important. Updated, evidence-based guidelines from the HIV Medicine Association (HIVMA) and the Infectious Diseases Society of America (IDSA) are designed to help providers manage the care of those living with this complex chronic infection.
A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs.
The results are online and scheduled for publication in an upcoming issue of the Lancet.
